Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Development of PD Linked to Mitochondrial Damage

By LabMedica International staff writers
Posted on 27 Jun 2018
An international team of neurodegenerative disease researchers has suggested a mechanism that links mitochondrial damage caused by insoluble fibrils of alpha-synuclein to the development of Parkinson's disease.

The accumulation of misfolded alpha-synuclein amyloid fibrils leads to the formation of insoluble aggregates that have been implicated in several neurodegenerative diseases including Parkinson's disease, dementia with Lewy bodies, and Alzheimer's disease. More...
It has been exceedingly difficult to define the structure of alpha-synuclein fibrils due to their insolubility and complexity. Multiplication of alpha-synuclein encoding gene (SNCA) is correlated with early onset of the disease.

Investigators at The Francis Crick Institute (London, United Kingdom) and several British and American research institutes adopted a range of methods including single-molecule biophysical measurements, super-resolution microscopy, electrophysiology, and dynamic fluorescent neuronal imaging to describe the location and functional mechanism of oligomeric species of alpha-synuclein, compared to monomeric species. In addition, they generated neurons bearing a SNCA triplication mutation from pluripotent stem cells (iPSC).

Results published in the June 12, 2018, online edition of the journal Nature Communication revealed that aggregation of alpha-synuclein monomers generated beta sheet-rich oligomers that localized to the mitochondria in close proximity to several mitochondrial proteins including ATP synthase. Oligomers induced selective oxidation of the ATP synthase beta subunit and mitochondrial lipid peroxidation.

These oxidation events increased the probability of permeability transition pore (PTP) opening, triggering mitochondrial swelling, and ultimately cell death. Notably, inhibition of oligomer-induced oxidation prevented the pathological induction of PTP. Inducible pluripotent stem cells (iPSC)-derived neurons bearing SNCA triplication, generated alpha-synuclein aggregates that interacted with the ATP synthase and induced PTP opening, leading to neuronal death.

Senior author Dr. Sonia Gandhi, group leader at The Francis Crick Institute, said, "Our findings give us huge insight into why protein clumping is so damaging in Parkinson's, and highlight the need to develop therapies against the toxic form of alpha-synuclein, not the healthy non-clumped form."

Related Links:
The Francis Crick Institute


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Pipette
Accumax Smart Series
New
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Immunology

view channel
Image: Prof. Nicholas Schwab has found a biomarker that can predict treatment outcome of glatirameracetate in MS patients (Photo courtesy of Uni MS - M. Ibrahim)

Simple Genetic Testing Could Predict Treatment Success in Multiple Sclerosis Patients

Multiple sclerosis (MS) patients starting therapy often face a choice between interferon beta and glatiramer acetate, two equally established and well-tolerated first-line treatments. Until now, the decision... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.